Milestones

Established in September 2000, Shanghai Model Organisms Center Inc. has stayed true to its commitment to gene editing and the decoding of the language of life. Through our focus on the field of model organisms and our specialization in R&D, breeding and analysis of genetically-engineered animal models, we provide universities, research institutes, hospitals and pharmaceutical companies across the world with comprehensive, convenient and professional technical services and model resources.

Milestones

  • Founding of Shanghai Model Organisms Center in Sep. 2000

  • Established the R&D base for animal models of disease (biotechnology field) with support from the "863" program directed by the Ministry of Science and Technology in Nov. 2000

  • Completed construction of SPF animal rooms and embryo micro-manipulation experimental facilities in 2001

  • Successful generation of 1st SMOC transgenic mice in 2002

  • Successful generation of 1st SMOC knockout mice in 2003

  • Included as one of the first R&D public service platforms in Shanghai in 2007

  • Establishment of zebrafish research platform in 2008

  • Establishment of C. elegans research platform in 2010

  • Recognized as Shanghai Professional Technical Service Platform for Animal Models in 2011

  • Recognized as Shanghai High and New Technology Enterprise (HNTE) in 2011

  • Recognized as Shanghai Engineering and Technological Research Center for Animal Models in 2012

  • Obtained AAALAC accreditation in 2012

  • Recognized as Shanghai Professional Technical Service Platform for Comparative Medicine in 2015

  • Series A funding in 2015

  • Transformed into a joint-stock company and renamed as Shanghai Model Organisms Center, Inc. in Jun. 2016

  • Completed NEEQ listing, stock code 839728 in Nov. 2016

  • Recognized as Shanghai Science and Technology Little Giant Enterprise in 2017

  • Brand upgrading in 2018

  • Establishment of preclinical efficacy evaluation service platform in 2019

  • Series B funding in 2020

  • SMOC(stock code:688265) launched into SSE STAR Market in 2021

Popular articles

Tamoxifen诱导Cre-ERT2小鼠 使用指南

Cre-ERT2在无Tamoxifen诱导的情况下，在细胞质内处于无活性状态；当Tamoxifen诱导后，Tamoxifen的代谢产物4-OHT（雌激素类似物）与ERT结合，可使Cre-ERT2进核发挥Cre重组酶活性。

Learn more
Cre-lox系统介绍及使用汇总

你一定听说过Cre-lox重组系统，无论你是否直接进行过基因操作。由于Cre-lox系统具有操作简单、重组率高的优点，如今已经成为体内外遗传操作的强有力工具。利用Cre-lox系统，可以在特定细胞、组织或整个生物体，甚至在特定时间点敲除或表达某个基因，实现对特定基因的时空特异性操作，这对基因功能的研究和人类疾病动物模型的建立都具有深刻影响。

Learn more